MDS Pharma Services Names Dr. James Pusey to Lead Global Clinical Development
11 Mai 2007 - 3:00PM
PR Newswire (US)
KING OF PRUSSIA, PA, May 11 /PRNewswire-FirstCall/ -- MDS Pharma
Services, a leading provider of innovative drug discovery and
development solutions, has appointed Dr. James M. Pusey as
Vice-President and General Manager of its Global Clinical
Development business, which manages late-stage clinical drug
trials. Dr. Pusey brings more than 25 years of experience in
medicine, global clinical trial management, contract research
organization services, and global pharmaceutical sales, marketing
and operations. Before joining MDS, Dr. Pusey was President and CEO
of OrthoLogic, Inc., a biotech company, where he put in place a
strategic plan involving collaborative agreements and acquisitions.
Prior to that role, he was Executive Vice-President for Neurology
at Serono, Inc., where he was accountable for late-stage drug
development, including co-development projects with Pfizer. In
addition, he has held the positions of Vice-President of Marketing
and Therapeutic Area Leader for Central Nervous System, Pain and
Infection at Astra-Zeneca USA. "Dr. Pusey's vast industry
experience combined with his medical background will enhance our
ability to assess client needs and provide exceptional service
managing their most demanding clinical trials," said MDS Pharma
Services President David Spaight. Dr. Pusey began his career in
medical practice in London, where he worked on the staff of four
London hospitals. He also served as the International Medical
Advisor in Southeast Asia, where he managed anti-viral drug
development trials for The Wellcome Foundation, Ltd. His career in
the pharmaceutical industry began at SmithKlineBeecham (SKB) as
International Marketing Manager for two hospital antibiotics. He
later served as General Manager of SKB - New Zealand and
Vice-President and General Manager of the company's global Clinical
Trials Center before moving to other senior leadership roles.
Educated at London University, he holds Bachelor of Medicine and
Bachelor of Surgery degrees from the Royal Free Hospital School of
Medicine, and an MBA from the London Business School. Dr. Pusey
will lead a business area that is focused upon enhancing client
service through its LeanSigma and other initiatives to improve
process efficiency and support client needs. MDS Pharma Services
has also been recognized as the top contract research organization
in Europe in the 2006 Thomson Center Watch survey of investigators,
the preferred CRO of the Multiple Myeloma Research Consortium, and
as the most promising CRO in Asia in the 2006 Frost & Sullivan
CRO Awards. About MDS Pharma Services MDS Pharma Services offers a
full spectrum of resources to meet the drug discovery and
development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around
the world, we apply advanced scientific and technological expertise
throughout the drug discovery and development process - from lead
optimization, pre-IND research, early clinical research
(bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized
cardiac services. For more information, visit our website at
http://www.mdsps.com/. MDS Pharma Services is a business unit of
MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that
provides market-leading products and services that our customers
need for the development of drugs and diagnosis and treatment of
disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than
6,200 highly skilled people in 28 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Pharma Services CONTACT: For Investors, Sharon
Mathers, (416) 675-6777 ext. 34721, ; For Media, Charlene McGrady,
(610) 239-7900 ext. 231,
Copyright